Skip to main content

Boceprevir Dosage

Applies to the following strengths: 200 mg

Usual Adult Dose for Chronic Hepatitis C

800 mg orally 3 times a day (7 to 9 hours apart) with food

In Patients without Cirrhosis Who Are Previously Untreated or Who Previously Failed Interferon and Ribavirin Therapy (HCV-RNA levels should be monitored at treatment weeks [TWs] 8, 12, and 24 to determine duration of therapy and assess for treatment futility):
Previously untreated patients:

Previous partial responders or relapsers:

Previous null responders:

In Patients with Compensated Cirrhosis:



USE: For the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in patients with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy, including prior null responders, partial responders, and relapsers

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

No adjustment recommended.


Dose Adjustments

The dose of this drug should not be reduced.

The manufacturer product information for peginterferon alfa and/or ribavirin should be consulted for appropriate dose reduction and/or discontinuation due to side effects. If peginterferon alfa or ribavirin is stopped for any reason, this drug must also be discontinued.


In Combination with Peginterferon alfa and Ribavirin:

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.


No adjustment recommended.

Other Comments

Administration advice:

Storage requirements:



Patient advice:

Frequently asked questions

More about boceprevir

Patient resources

Other brands


Professional resources

Other brands


Related treatment guides

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.